{
  "extraction_metadata": {
    "timestamp": "2025-09-04T14:56:21.440846",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 4,
    "total_picos": 17
  },
  "picos_by_country": {
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        },
        {
          "Population": "Adults with cancer from Sotorasib docetaxel, Used routinely in non-small cell lung clinical practice; Docetaxel + nintedanib * advanced (CPNPC) cells It is validated for their mutated KRAS G12C and Lumykras (Sotorasib) indication/ population that have progressed after at least one prior systemic therapy line.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, quality of life, safety"
        }
      ],
      "ChunksUsed": 35,
      "ContextTokens": 8607
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with NDRP with a KRAS G12C mutation after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel (DOC)",
          "Outcomes": "progression-free survival, overall response rate, disease control rate, quality of life, safety"
        },
        {
          "Population": "patients with NDRP with a KRAS G12C mutation after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel (NIN+DOC)",
          "Outcomes": "progression-free survival, overall response rate, disease control rate, quality of life, safety"
        },
        {
          "Population": "patients with NDRP with a KRAS G12C mutation after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (PMX)",
          "Outcomes": "progression-free survival, overall response rate, disease control rate, quality of life, safety"
        }
      ],
      "ChunksUsed": 35,
      "ContextTokens": 8056
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 3288
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel (only for patients with PD-L1 negative tumours)",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (only for patients with PD-L1 negative tumours and except in cases predominantly squamous histology)",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expr â‰¥ 1% of tumour cells))",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
          "Outcomes": "overall survival, progression-free survival, health status, symptomatology, health-related quality of life, side effects"
        }
      ],
      "ChunksUsed": 35,
      "ContextTokens": 8531
    }
  }
}